Quanterix Corporation (QTRX)
After hours:
| Previous close | 16.92 |
| Open | 17.19 |
| Bid | 16.91 x 100 |
| Ask | 17.04 x 200 |
| Day's range | 16.67 - 17.67 |
| 52-week range | 15.32 - 29.70 |
| Volume | |
| Avg. volume | 372,746 |
| Market cap | 650.966M |
| Beta (5Y monthly) | 1.33 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.86 |
| Earnings date | 07 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 28.40 |
Business WireQuanterix To Report First Quarter 2024 Financial Results
BILLERICA, Mass., April 29, 2024--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will host a conference call on Wednesday, May 8, 2024 at 8:30 a.m. E.T., to discuss its first quarter 2024 financial results.
Simply Wall St.Investing in Quanterix (NASDAQ:QTRX) a year ago would have delivered you a 111% gain
Quanterix Corporation ( NASDAQ:QTRX ) shareholders might be concerned after seeing the share price drop 13% in the last...
Business WireQuanterix Outlines Partner Path With Labs to Expedite Building Global Alzheimer’s Disease Testing Infrastructure
BILLERICA, Mass., March 21, 2024--Quanterix Corporation (NASDAQ: QTRX), a leading provider of ultra-sensitive research products and high-definition diagnostics, today announced a specific partnership path for laboratories interested in offering Tau based research and diagnostic testing services. Quanterix has secured over thirty U.S. patents protecting our innovative ultra-sensitive research products and high-definition diagnostics, and we continue to secure additional patent protection, both in
